Barclays Maintains Overweight on Lumexa Imaging Hldgs, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 86.6%

Neg 86.6% Neu 0% Pos 0%

Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $23 to $15.